Nasdaq: LIMN/Biotechnology
Liminatus Pharma, Inc.
Cerritos, CA, United States
Company overview
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.